166 related articles for article (PubMed ID: 37160943)
1. Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease.
Palaniyandi S; Strattan E; Kumari R; Mysinger M; Hakim N; Kesler MV; Apatira M; Bittencourt F; Wang L; Jia Z; Gururaja TL; Hill RJ; Hildebrandt GC
Bone Marrow Transplant; 2023 Aug; 58(8):924-935. PubMed ID: 37160943
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice.
Schutt SD; Fu J; Nguyen H; Bastian D; Heinrichs J; Wu Y; Liu C; McDonald DG; Pidala J; Yu XZ
PLoS One; 2015; 10(9):e0137641. PubMed ID: 26348529
[TBL] [Abstract][Full Text] [Related]
3. Pretransplant Short-Term Exposure of Donor Graft Cells to ITK Selective Inhibitor Ameliorates Acute Graft-versus-Host Disease by Inhibiting Effector T Cell Differentiation while Sparing Regulatory T Cells.
Kondo T; Ikegawa S; Fukumi T; Sumii Y; Sugiura H; Sando Y; Nakamura M; Meguri Y; Iwamoto M; Maeda Y; Matsuoka KI
Immunohorizons; 2021 Jun; 5(6):424-437. PubMed ID: 34112701
[TBL] [Abstract][Full Text] [Related]
4. Successful management of acute graft-versus-host disease with ibrutinib during cord blood transplantation for germline
Uchimura A; Yasuda H; Onagi H; Inano T; Shirane S; Ishii M; Azusawa Y; Hamano Y; Eguchi H; Arai M; Ando J; Ando M
Heliyon; 2024 Jan; 10(2):e24801. PubMed ID: 38312561
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.
Dubovsky JA; Flynn R; Du J; Harrington BK; Zhong Y; Kaffenberger B; Yang C; Towns WH; Lehman A; Johnson AJ; Muthusamy N; Devine SM; Jaglowski S; Serody JS; Murphy WJ; Munn DH; Luznik L; Hill GR; Wong HK; MacDonald KK; Maillard I; Koreth J; Elias L; Cutler C; Soiffer RJ; Antin JH; Ritz J; Panoskaltsis-Mortari A; Byrd JC; Blazar BR
J Clin Invest; 2014 Nov; 124(11):4867-76. PubMed ID: 25271622
[TBL] [Abstract][Full Text] [Related]
6. Targeting Bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in mice.
Chen X; Wang Y; Huang X; Geng S; Li C; Zeng L; Huang L; Du X; Weng J; Lai P
Int Immunopharmacol; 2023 Apr; 117():109746. PubMed ID: 36827923
[TBL] [Abstract][Full Text] [Related]
7. Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT.
Mammadli M; Huang W; Harris R; Sultana A; Cheng Y; Tong W; Pu J; Gentile T; Dsouza S; Yang Q; Bah A; August A; Karimi M
Front Immunol; 2020; 11():593863. PubMed ID: 33324410
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice.
Pai CS; Khuat LT; Chen M; Murphy WJ; Abedi M
Biol Blood Marrow Transplant; 2017 Jan; 23(1):30-37. PubMed ID: 27815049
[TBL] [Abstract][Full Text] [Related]
9. CCL1 blockade alleviates human mesenchymal stem cell (hMSC)-induced pulmonary fibrosis in a murine sclerodermatous graft-versus-host disease (Scl-GVHD) model.
Lim JY; Ryu DB; Kim TW; Lee SE; Park G; Yoon HK; Min CK
Stem Cell Res Ther; 2020 Jun; 11(1):254. PubMed ID: 32586381
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Bruton's tyrosine kinase and IL-2 inducible T-cell kinase suppresses both neutrophilic and eosinophilic airway inflammation in a cockroach allergen extract-induced mixed granulocytic mouse model of asthma using preventative and therapeutic strategy.
Nadeem A; Ahmad SF; Al-Harbi NO; Ibrahim KE; Siddiqui N; Al-Harbi MM; Attia SM; Bakheet SA
Pharmacol Res; 2019 Oct; 148():104441. PubMed ID: 31505252
[TBL] [Abstract][Full Text] [Related]
11. Kinase Inhibition as Treatment for Acute and Chronic Graft-
Braun LM; Zeiser R
Front Immunol; 2021; 12():760199. PubMed ID: 34868001
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of EGFR Tyrosine Kinase by Erlotinib Prevents Sclerodermatous Graft-Versus-Host Disease in a Mouse Model.
Morin F; Kavian N; Marut W; Chéreau C; Cerles O; Grange P; Weill B; Nicco C; Batteux F
J Invest Dermatol; 2015 Oct; 135(10):2385-2393. PubMed ID: 25938558
[TBL] [Abstract][Full Text] [Related]
13. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.
Flynn R; Paz K; Du J; Reichenbach DK; Taylor PA; Panoskaltsis-Mortari A; Vulic A; Luznik L; MacDonald KK; Hill GR; Nyuydzefe MS; Weiss JM; Chen W; Trzeciak A; Serody JS; Aguilar EG; Murphy WJ; Maillard I; Munn D; Koreth J; Cutler CS; Antin JH; Ritz J; Waksal SD; Zanin-Zhorov A; Blazar BR
Blood; 2016 Apr; 127(17):2144-54. PubMed ID: 26983850
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Ibrutinib for Chronic Graft-Versus-Host Disease: A Systematic Review.
Santosa D; Rizky D; Tandarto K; Kartiyani I; Yunarvika V; Ardini DNE; Setiawan B; Pangarsa EA; Suharti C
Asian Pac J Cancer Prev; 2023 Dec; 24(12):4025-4033. PubMed ID: 38156834
[TBL] [Abstract][Full Text] [Related]
15. Mast Cells Are Mediators of Fibrosis and Effector Cell Recruitment in Dermal Chronic Graft-vs.-Host Disease.
Strattan E; Palaniyandi S; Kumari R; Du J; Hakim N; Huang T; Kesler MV; Jennings CD; Sturgill JL; Hildebrandt GC
Front Immunol; 2019; 10():2470. PubMed ID: 31681336
[TBL] [Abstract][Full Text] [Related]
16. Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease.
Le Huu D; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Tedder TF; Fujimoto M
Blood; 2013 Apr; 121(16):3274-83. PubMed ID: 23422748
[TBL] [Abstract][Full Text] [Related]
17. Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice.
Radojcic V; Paz K; Chung J; Du J; Perkey ET; Flynn R; Ivcevic S; Zaiken M; Friedman A; Yan M; Pletneva MA; Sarantopoulos S; Siebel CW; Blazar BR; Maillard I
Blood; 2018 Nov; 132(20):2188-2200. PubMed ID: 30181175
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.
Jung U; Foley JE; Erdmann AA; Toda Y; Borenstein T; Mariotti J; Fowler DH
Biol Blood Marrow Transplant; 2006 Sep; 12(9):905-18. PubMed ID: 16920556
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice.
Murphy WJ; Welniak LA; Taub DD; Wiltrout RH; Taylor PA; Vallera DA; Kopf M; Young H; Longo DL; Blazar BR
J Clin Invest; 1998 Nov; 102(9):1742-8. PubMed ID: 9802888
[TBL] [Abstract][Full Text] [Related]
20. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.
Le Huu D; Kimura H; Date M; Hamaguchi Y; Hasegawa M; Hau KT; Fujimoto M; Takehara K; Matsushita T
J Dermatol Sci; 2014 Jun; 74(3):214-21. PubMed ID: 24679982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
